Castle (CSTL) Q1 2026 Earnings Transcript

Castle Biosciences reported Q1 revenue of $83.7 million, with core test report volumes up 36% year over year, and raised full-year revenue guidance to $345 million-$355 million from $340 million-$350 million. DecisionDx-Melanoma reports rose 16% to 10,021 and TissueCypher volumes jumped 58% to 11,745, while gross margin improved to 72.8% and net loss narrowed to $14.5 million from $25.8 million. Management also reiterated a 2026 FDA submission timeline for the melanoma test, highlighted 650 early orders for Advanced ADTx, and said M&A remains part of the growth strategy.

Analysis

The key signal is not just the revenue beat; it is that Castle is starting to show operating leverage in the *mix* of its growth. TissueCypher is now large enough to absorb seasonal softness in Q1, which implies that the market should stop treating quarterly volatility as execution risk and start treating it as a function of GI procedure timing. That matters because if management is right about adding roughly the same number of tests as last year, the business is moving into a phase where incremental upside can re-rate the name even without a step-change in reimbursement.

The bigger second-order issue is that the ADA/derm pipeline is being funded by a core franchise that is still under-penetrated, but the company is choosing to throttle ADTx access. That means the market is likely underestimating optionality: a limited rollout with 650 orders suggests genuine pull, yet the near-term P&L impact stays muted because management can keep the launch capital-light until reimbursement visibility improves. In other words, Castle may be able to preserve gross margin while creating a future catalyst stack in 2H26 from ADTx reimbursement clarity, melanoma FDA submission timing, and potential Medicare movement on SCC.

Consensus is probably too focused on the quarter’s cash burn and too dismissive of the quality of the growth. The cash outflow was front-loaded and not obviously structural, while the bigger bear case would require either a sharp slowdown in melanoma/TissueCypher volumes or a reimbursement stall that forces a longer period of gated ADTx expansion. Absent that, the setup is one of a profitable-enough growth story with multiple self-funded catalysts over the next 6-12 months.

From a relative-value lens, the market may be missing that Castle is behaving less like a one-product diagnostics story and more like a platform with three shots on goal, two of which are already scaling and one of which is still intentionally suppressed. The near-term rerating likely comes from sustained monthly volume prints, not from earnings margin expansion alone, so the trade should be built around catalyst timing rather than valuation optically looking cheap.

Key Decisions for Investors

• Long CSTL into 2H26 catalyst stack, using a 3-6 month horizon; risk/reward favors upside if TissueCypher stays on a ratable growth path and ADTx reimbursement clarity lands by end-Q3.
• Buy CSTL on post-earnings consolidation rather than strength; the quarter’s seasonal cash burn creates a better entry than chasing the gap, with downside defined if monthly volumes flatten in May-June.
• Use a call spread in CSTL (6-9 month tenor) to express upside from FDA submission/reimbursement milestones while limiting exposure to reimbursement-delay downside.
• Pair trade: long CSTL / short a lower-quality diagnostics grower with weaker volume momentum and higher dependence on one franchise; the relative trade should work if investors rotate toward self-funded growth with multiple catalysts.
• Set a risk trigger to reduce exposure if TissueCypher sequential growth remains negative in 2Q or if management narrows ADTx access further without reimbursement progress, as that would signal the growth stack is being pushed out in time.